144 related articles for article (PubMed ID: 9298807)
21. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
[TBL] [Abstract][Full Text] [Related]
22. Analytical approaches relating genetic evolutionary pathways to prognostic factors.
Rohloff AC; Sakach JM; Shackney SE
Cytometry; 1995 Sep; 21(1):23-9. PubMed ID: 8529467
[TBL] [Abstract][Full Text] [Related]
23. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
25. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
26. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
28. [Genetic abnormalities in lung cancer and their prognostic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1996 Jul; 23(8):990-6. PubMed ID: 8687234
[TBL] [Abstract][Full Text] [Related]
29. Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas.
Sugai T; Takahashi H; Habano W; Nakamura S; Sato K; Orii S; Suzuki K
J Pathol; 2003 Jun; 200(2):168-76. PubMed ID: 12754737
[TBL] [Abstract][Full Text] [Related]
30. Evidence for common clonal origin of multifocal lung cancers.
Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection.
Liang JT; Chang KJ; Chen JC; Lee CC; Cheng YM; Hsu HC; Chien CT; Wang SM
Hepatogastroenterology; 1999; 46(26):883-90. PubMed ID: 10370632
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
[TBL] [Abstract][Full Text] [Related]
33. Chronic inflammatory bowel disease and cancer.
Pohl C; Hombach A; Kruis W
Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
[TBL] [Abstract][Full Text] [Related]
34. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
36. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
37. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
38. Guilt by association? p53 and the development of aneuploidy in cancer.
Duensing A; Duensing S
Biochem Biophys Res Commun; 2005 Jun; 331(3):694-700. PubMed ID: 15865924
[TBL] [Abstract][Full Text] [Related]
39. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers.
Janocko LE; Brown KA; Smith CA; Gu LP; Pollice AA; Singh SG; Julian T; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Cytometry; 2001 Jun; 46(3):136-49. PubMed ID: 11449404
[TBL] [Abstract][Full Text] [Related]
40. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
